Disease Definition: Solitary fibrous tumor (SFT), also known as fibrous tumor of the pleura, is a rare mesenchymal tumor originating in the pleura or at virtually any site in the soft tissue including seminal vesicle. Approximately 78% to 88% of SFT's are benign and 12% to 22% are malignant. It is a heterogeneous group of rare spindle-cell tumors that include benign and malignant neoplasms. Their cell of origin is still debated. SFT is preferred by most pathologists as a better term than “hemangiopericytoma” that gathers numerous unrelated entities and is presently only employed by neuropathologists. We focus the present paper on the forms of this family of tumors occurring in adult patients. There are 3 typical primary locations: pleural, meningeal and extrathoracic soft tissue.
Disease Symptoms: Patients present with proptosis and possibly ptosis, eyelid swelling, tearing, diplopia or decreased vision. Malignant infiltrating lesions can sometimes cause pain.
Disease Treatment: Because even benign-appearing solitary fibrous tumors (SFTs) can be locally recurrent and metastatic, wide resection of both benign and malignant SFTs is recommended. Preoperative vascular studies and arterial embolization should be considered because of the known bleeding risk with resection. Careful exclusion of other diagnoses (eg, synovial sarcoma) is important. Because of the favorable outcome with SFTs, it may be possible to avoid limb-threatening and deforming operations. No evidence suggests that adjuvant chemotherapy is beneficial. If the SFTR appears malignant histologically, adjuvant radiation therapy may be considered. Long-term follow-up is recommended because local and distant relapse is possible, even with benign-appearing tumors.
Statistics: Solitary fibrous tumor (SFT), usually described in the pleura, is exceedingly rare in the prostate. We report a 60-year-old man with prostatic SFT revealed by obstructive urinary symptoms, and detected by ultrasonography. Computed tomography (CT) and magnetic resonance imaging suggested a prostatic origin. CT-guided tumor biopsy diagnosed a SFT. A cystoprostatectomy was performed. Pathologic examination showed a 15-cm tumor arising from the prostate and showing histological criteria suggestive of aggressiveness. The surgical resection margins were tumor-free. The patient was then regularly monitored and is still alive in complete remission, 28 months after surgery. In conclusion, we report a new exceptional case of prostatic SFT. We review the literature and discuss the challenging issues of misdiagnosis, prognosis and treatment in canada.